Gene expression alterations in bipolar disorder postmortem brains

Bipolar Disorders

Volumn 15, Issue 2, 2013, Pages 177-187

  Chen, Haiming ^a   Wang, Nulang ^a   Zhao, Xin ^a   Ross, Christopher A ^b   O'Shea, K Sue ^a   Mcinnis, Melvin G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotics; Microarray; Synapse; Transport

Indexed keywords

AMFEBUTAMONE; BENZATROPINE; CARBAMAZEPINE; CHLORPROTHIXENE; CLOMIPRAMINE; CLOZAPINE; DIPHENHYDRAMINE; FLUOXETINE; HALOPERIDOL; LITHIUM; PROTEIN BAG3; PROTEIN BCL 2; RGS4 PROTEIN; RISPERIDONE; SERTRALINE; SYNAPSIN II; THIORIDAZINE; TIOTIXENE; TRAZODONE; UNCLASSIFIED DRUG; VALPROIC ACID; VENLAFAXINE;

ADULT; ARTICLE; AUTOPSY; BIOGENESIS; BIOINFORMATICS; BIPOLAR DISORDER; CELL COMMUNICATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE ONTOLOGY; GENETIC PROCEDURES; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; INTRACELLULAR TRANSPORT; MALE; MICROARRAY ANALYSIS; NEUROPATHOLOGY; PRIORITY JOURNAL; RANVIER NODE; SYNAPSE VESICLE;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BRAIN; EUKARYOTIC INITIATION FACTORS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POSTMORTEM CHANGES;

EID: 84874232958     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12039     Document Type: Article

References (49)

1. Goodwin FK, Jamison KR. Manic Depressive Illness. New York: Oxford University Press, 1990.
2. Gershon ES, Hamovit J, Guroff JJ et al.A family study of schizoaffective, bipolar I, bipolar II, unipolar, and normal control probands. Arch Gen Psychiatry 1982; 39: 1157-1167.
3. Bertelsen A, Harvald B, Hauge M. A Danish twin study of manic-depressive disorders. Br J Psychiatry 1977; 130: 330-351.
4. Mendlewicz J, Rainer JD. Adoption study supporting genetic transmission in manic-depressive illness. Nature 1977; 268: 327-329.
5. Serretti A, Mandelli L. The genetics of bipolar disorder: genome 'hot regions, ' genes, new potential candidates and future directions. Mol Psychiatry 2008; 13: 742-771.
6. Craddock N, Khodel V, Van EP, Reich T. Mathematical limits of multilocus models: the genetic transmission of bipolar disorder. Am J Hum Genet 1995; 57: 690-702.
7. Crow TJ. How and why genetic linkage has not solved the problem of psychosis: review and hypothesis. Am J Psychiatry 2007; 164: 13-21.
8. Iwamoto K, Kakiuchi C, Bundo M, Ikeda K, Kato T. Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorders. Mol Psychiatry 2004; 9: 406-416.
9. Jurata LW, Bukhman YV, Charles V et al.Comparison of microarray-based mRNA profiling technologies for identification of psychiatric disease and drug signatures. J Neurosci Methods 2004; 138: 173-188.
10. Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet 2005; 14: 241-253.
11. Tsuang MT, Nossova N, Yager T et al.Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: a preliminary report. Am J Med Genet B Neuropsychiatr Genet 2005; 133: 1-5.
12. Ryan MM, Lockstone HE, Huffaker SJ, Wayland MT, Webster MJ, Bahn S. Gene expression analysis of bipolar disorder reveals downregulation of the ubiquitin cycle and alterations in synaptic genes. Mol Psychiatry 2006; 11: 965-978.
13. Choudary PV, Molnar M, Evans SJ et al.Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA 2005; 102: 15653-15658.
14. Bousman CA, Chana G, Glatt SJ et al.Preliminary evidence of ubiquitin proteasome system dysregulation in schizophrenia and bipolar disorder: convergent pathway analysis findings from two independent samples. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 494-502.
15. Chu TT, Liu Y, Kemether E. Thalamic transcriptome screening in three psychiatric states. J Hum Genet 2009; 54: 665-675.
16. Choi KH, Higgs BW, Wendland JR, Song J, McMahon FJ, Webster MJ. Gene expression and genetic variation data implicate PCLO in bipolar disorder. Biol Psychiatry 2011; 69: 353-359.
17. Elashoff M, Higgs BW, Yolken RH et al.Meta-analysis of 12 genomic studies in bipolar disorder. J Mol Neurosci 2007; 31: 221-243.
18. Torrey EF, Webster M, Knable M, Johnston N, Yolken RH. The Stanley Foundation Brain Collection and Neuropathology Consortium. Schizophr Res 2000; 44: 151-155.
19. Popova T, Mennerich D, Weith A, Quast K. Effect of RNA quality on transcript intensity levels in microarray analysis of human post-mortem brain tissues. BMC Genomics 2008; 9: 91.
20. Irizarry RA, Hobbs B, Collin F et al.Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264.
21. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004; 20: 307-315.
22. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-5121.
23. Holland PM, Abramson RD, Watson R, Gelfand DH. Detection of specific polymerase chain reaction product by utilizing the 5'-3' exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA 1991; 88: 7276-7280.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
25. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol 2003; 4: R70.
26. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000; 28: 27-30.
27. Prasad KM, Almasy L, Gur RC et al.RGS4 polymorphisms associated with variability of cognitive performance in a family-based schizophrenia sample. Schizophr Bull 2010; 36: 983-990.
28. Dean B, Boer S, Gibbons A, Money T, Scarr E. Recent advances in postmortem pathology and neurochemistry in schizophrenia. Curr Opin Psychiatry 2009; 22: 154-160.
29. Ikeda M, Tomita Y, Mouri A et al.Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. Biol Psychiatry 2010; 67: 263-269.
30. Lane HY, Liu YC, Huang CL et al.RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia. J Clin Psychopharmacol 2008; 28: 64-68.
31. Thomas EA. Molecular profiling of antipsychotic drug function: convergent mechanisms in the pathology and treatment of psychiatric disorders. Mol Neurobiol 2006; 34: 109-128.
32. Li JZ, Vawter MP, Walsh DM et al.Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions. Hum Mol Genet 2004; 13: 609-616.
33. Danglot L, Galli T. What is the function of neuronal AP-3?Biol Cell 2007; 99: 349-361.
34. Carter CJ. eIF2B and oligodendrocyte survival: where nature and nurture meet in bipolar disorder and schizophrenia?Schizophr Bull 2007; 33: 1343-1353.
35. Brennand KJ, Simone A, Jou J et al.Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011; 473: 221-225.
36. Le-Niculescu H, Patel SD, Bhat M et al.Convergent functional genomics of genome-wide association data for bipolar disorder: comprehensive identification of candidate genes, pathways and mechanisms. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 155-181.
37. Lee SH, DeCandia TR, Ripke S et al.Estimating the proportion of variation in susceptibility to schizophrenia captured by common SNPs. Nat Genet 2012; 44: 247-250.
38. Chen R, Mias GI, Li-Pook-Than J et al.Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012; 148: 1293-1307.
39. Craddock N, O'Donovan MC, Owen MJ. The genetics of schizophrenia and bipolar disorder: dissecting psychosis. J Med Genet 2005; 42: 193-204.
40. Li Y, Zhao Q, Zhang Z et al.Association study between RGS4 and bipolar disorder in the Chinese Han population. Psychiatr Genet 2010; 20: 130-132.
41. Le-Niculescu H, Balaraman Y, Patel S et al.Towards understanding the schizophrenia code: an expanded convergent functional genomics approach. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 129-158.
42. Yang P, Baker KA, Hagg T. The ADAMs family: coordinators of nervous system development, plasticity and repair. Prog Neurobiol 2006; 79: 73-94.
43. Jope RS. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 1999; 4: 117-128.
44. Binder EB. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 2009; 34 (Suppl. 1): S186-S195.
45. Willour VL, Chen H, Toolan J et al.Family-based association of FKBP5 in bipolar disorder. Mol Psychiatry 2009; 14: 261-268.
46. Ferreira MA, O'Donovan MC, Meng YA et al.Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet 2008; 40: 1056-1058.
47. Quinn EM, Hill M, Anney R, Gill M, Corvin AP, Morris DW. Evidence for cis-acting regulation of ANK3 and CACNA1C gene expression. Bipolar Disord 2010; 12: 440-445.
48. Takahashi K, Tanabe K, Ohnuki M et al.Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
49. Pang ZP, Yang N, Vierbuchen T et al.Induction of human neuronal cells by defined transcription factors. Nature 2011; 476: 220-223.